Presenilins as therapeutic targets for the treatment of Alzheimer's disease - PubMed (original) (raw)

Review

Presenilins as therapeutic targets for the treatment of Alzheimer's disease

T E Golde et al. Trends Mol Med. 2001 Jun.

Abstract

Studies demonstrating that accumulation and aggregation of the amyloid beta protein (Abeta) within the brain is likely to cause Alzheimer's disease (AD) have provided the rationale for therapeutic strategies aimed at influencing Abeta production, aggregation and clearance. gamma-secretase catalyzes the final cleavage that releases the Abeta from its precursor; therefore, it is a potential therapeutic target for the treatment of AD. Recent data show that the polytopic membrane proteins presenilin 1 and presenilin 2 are either catalytic components or essential co-factors of a membrane-bound proteolytic complex that possesses gamma-secretase activity. Although recent findings demonstrating that gamma-secretase inhibitors bind directly to presenilins (PSs) further support a catalytic role for PSs in gamma-secretase cleavage, additional studies are still needed to clarify the role of PSs in gamma-secretase cleavage and the use of targeting PSs to reduce Abeta production.

PubMed Disclaimer

Cited by

Gamma-secretase: substrates and inhibitors.
Rochette MJ, Murphy MP. Rochette MJ, et al. Mol Neurobiol. 2002 Aug;26(1):81-95. doi: 10.1385/MN:26:1:081. Mol Neurobiol. 2002. PMID: 12392058
Recent rodent models for Alzheimer's disease: clinical implications and basic research.
Braidy N, Muñoz P, Palacios AG, Castellano-Gonzalez G, Inestrosa NC, Chung RS, Sachdev P, Guillemin GJ. Braidy N, et al. J Neural Transm (Vienna). 2012 Feb;119(2):173-95. doi: 10.1007/s00702-011-0731-5. Epub 2011 Nov 16. J Neural Transm (Vienna). 2012. PMID: 22086139 Review.
Evidence of a novel mechanism for partial γ-secretase inhibition induced paradoxical increase in secreted amyloid β protein.
Barnwell E, Padmaraju V, Baranello R, Pacheco-Quinto J, Crosson C, Ablonczy Z, Eckman E, Eckman CB, Ramakrishnan V, Greig NH, Pappolla MA, Sambamurti K. Barnwell E, et al. PLoS One. 2014 Mar 21;9(3):e91531. doi: 10.1371/journal.pone.0091531. eCollection 2014. PLoS One. 2014. PMID: 24658363 Free PMC article.
Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice.
Dewachter I, Reversé D, Caluwaerts N, Ris L, Kuipéri C, Van den Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mercken M, Godaux E, Van Leuven F. Dewachter I, et al. J Neurosci. 2002 May 1;22(9):3445-53. doi: 10.1523/JNEUROSCI.22-09-03445.2002. J Neurosci. 2002. PMID: 11978821 Free PMC article.
Genetics of Alzheimer's disease: a centennial review.
Ertekin-Taner N. Ertekin-Taner N. Neurol Clin. 2007 Aug;25(3):611-67, v. doi: 10.1016/j.ncl.2007.03.009. Neurol Clin. 2007. PMID: 17659183 Free PMC article. Review.

Presenilins as therapeutic targets for the treatment of Alzheimer's disease - PubMed (original) (raw)